/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company s 2023 Annual General Meeting of.
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and.
vTv Therapeutics (VTVT) Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.